TH87784A - Unique formula that contains O-desmethylvenlaphazine (ODV) or its salt - Google Patents

Abstract

DC60 (04/12/49) This invention provides a specific mixture of o-desmethylvenlafaxine (ODV), a selective serotonin reuptake inhibitor, and norepinephrine, or its pharmaceutically acceptable salts, in exact image. The invented specific formulation contains a substance that enhances transdermal/mucous absorption. It also provides the use of the preparations and applications of these mixtures for the treatment of various diseases or conditions such as vasoconstriction symptoms and pain. This invention provides a specific mixture of o-desmethylvenlafaxine (ODV), a selective serotonin reuptake inhibitor, and norepinephrine, or its pharmaceutically acceptable salts, in exact image. The invented specific formulation contains a substance that enhances transdermal/mucous absorption. It also provides the use of the preparations and applications of these mixtures for the treatment of various diseases or conditions such as vasoconstriction symptoms and pain.

Claims (25)

1. The specific mixture contains therapeutic amounts of the ODV, or its pharmacologically acceptable salt, and at least one physiologically acceptable carrier or drug additive. 2. The specific mixture of claim 1, whereby the mixture is a formulation selected from a group consisting of ointments, creams, lotions, patches, gels, sprays, aerosols and oils. 3. A specific mixture of claim 1 where the mixture is a cream or gel. 4. A specific mixture of any one of the claims 1 through 3 in which at least one physiologically acceptable carrier or filler is selected from a group consisting of tromethane ethanol, polyethylene glycol, glycerin, propylene glycol, acrylate, carbopol, purified water, benzyl alcohol, cetyl alcohol, citric acid, monoglyceride, diglyceride, triglyceride, oleyl alcohol, sodium cetostearyl sulfate, sodium hydroxide, stearyl alcohol, white petrolatum, mineral oil, propylene carbonate, white wax, paraffin and any combination thereof. 5. A specific mixture of any one of the claims 1 through 4, which includes at least one absorption enhancer. 6. A specific mixture of claim 5 in which at least one absorption enhancer is selected from a group consisting of pentadecalactone, 1,3-dioxalene, 1,3-dioxan and any combination thereof. 7. A specific mixture of any one of the claims 1 through 6, in addition to containing therapeutic amounts of at least one pharmacologically active substance. 8. A specific mixture of claim number 7 in which at least one pharmacologically active substance is selected. From the group comprising analgesics, anesthetics, muscle relaxants, neurotransmitter regulators, pain relievers, premenstrual syndrome (PMS) medications, menopausal medications, anti-aging medications, anti-anxiety medications, mood disorder medications, antidepressants, bipolar disorder medications, schizophrenic medications, sedatives, sleeping pills, migraine medications, skin cooling products, anticancer drugs, alkaloids, antimelanin drugs, blood pressure medications, hormones, steroids, anti-inflammatory drugs, medications for local ischemia, antiarrhythmias, vitamins, electrolytes, anti-angiogenesis drugs, wound healing drugs, cytokines, growth factors, antihistamines, antibacterial drugs, antiviral drugs, antibiotics, appetite suppressants, skin diseases such as skin regeneration drugs, sunscreens and moisturizers, aphrodisiacs, mild laxatives, antidiarrheals, antipruritics, antipyretics, and immunostimulants. And substances suitable for the treatment of diseases and preventive measures associated with or in combination with pain and inflammation, and any combination thereof. 9. A specific mixture of any one of the claims 1 through 8 in which the therapeutic effect amount of ODV or its pharmaceutically acceptable salt is between approximately 5 mg and approximately 500 mg, between approximately 25 mg and approximately 250 mg, or between approximately 50 mg and approximately 200 mg, where the amount is calculated based on the amount of base-free ODV. 10. A specific mixture of any one of the claims 1 through 8 in which the therapeutic effect amount of ODV or its pharmaceutically acceptable salt is approximately 100 mg, at a dose calculated based on the amount of ODV-free base. 11. The use of a specific combination of any one of the claims 1 through 7 to treat vasoconstriction symptoms in patients. 12. Use of claim 11 in regard to vasoconstriction symptoms including redness and warmth. 13. The use of claim 12 where the mixture is applied to one or more areas of skin of the patient's body that are red and burning. 14. Application of the 12th claim that the patient is a human being. 15. The use of claim 14 where the patient is female and has vasoconstriction symptoms combined with natural menopause, chemically induced menopause, or surgically induced menopause. 16. The use of claim 14 where the patient is a female patient who has received or has received treatment for breast cancer. 17. The use of claim 16 in the treatment of breast cancer which includes the administration of tamoxifene. 18. Application of claim 14 where the patient is a male patient with testosterone deficiency. 19. Use of claim number 18 in male patients who are being treated or have been treated for prostate cancer. 20. The use of a specific combination of any one of the claims in clauses 1 through 10 to treat pain in patients. 21. The use of claim 20 where the mixture is applied to one or more areas of the patient's body where they are experiencing pain. 22. The application of claim 21 states that pain experienced by the patient is a feeling of pain. 23. The application of claim 21 states that the pain experienced by the patient is nerve pain. 24. The use of any one of the claims 21 through 23 that the patient is a human being. 25. The use of ODV or its pharmaceutically acceptable salts, and at least one pharmaceutically acceptable carrier or additive in the preparation of a specific mixture, for the treatment of vasoconstriction symptoms or pain in patients.